MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced the publication in the journal PLOS One of a study in which miR-7 was examined in combination with the head and neck cancer (HNC) treatment erlotinib hydrochloride (Tarceva, Genentech/OSIP).
MiReven Announces Positive Preclinical Results for miR-7 in Head and Neck Cancer
Published on 25 October 2012
Leading Biology….. A New Weapon for Cancer
MiReven is commercialising the pioneering work of Prof Peter Leedman and Dr Keith Giles at the Harry Perkins Institute of Medical Research on the anti-cancer potential of miR-7.
- miReven Scientists Awarded $530k Grant to Advance miR-7 Cancer Therapeutic 19 November 2015
- microRNA-7: A tumor suppressor miRNA with therapeutic potential 24 July 2014
- MiReven Receives United States Patent 30 April 2014
- MiReven Wins 2013 Western Australia Innovator of the Year Award 14 November 2013